Comparison · NCT00115349-sae
Deferoxamine (DFO) and Deferiprone (L1) Combination Therapy vs Deferoxamine (DFO) + Monotherapy: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Deferoxamine (DFO) and Deferiprone (L1) Combination Therapy vs Deferoxamine (DFO) + Monotherapy: serious adverse events. Trial comparisons, record NCT00115349-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00115349-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.545 | 0.28 | 0.787 | wilson | |
| Risk in group 2 | 0.333 | 0.121 | 0.646 | wilson | |
| Risk difference, group 1 minus group 2 | 0.212 | -0.198 | 0.534 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.64 | 0.561 | 4.77 | log | |
| Odds ratio, group 1 over group 2 | 2.4 | 0.387 | 14.9 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Deferoxamine (DFO) and Deferiprone (L1) Combination Therapy than on Deferoxamine (DFO) + Monotherapy | 4.71 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Deferoxamine (DFO) and Deferiprone (L1) Combination Therapy | DFO + L1 DFO Administered daily at 50-60 mg/kg for 12-24 hr/day 7 days a week either subcutaneous or intravenous.~L1 Administered daily at 75 mg/kg in 3 divided doses taken orally and timed so that 2 of 3 doses will be simultaneous with DFO infusion. | 6 | 11 | EG000 |
| Group 2 | Deferoxamine (DFO) + Monotherapy | DFO + Placebo DFO Administered daily at 50-60 mg/kg for 12-24 hr/day 7 days a week either subcutaneous or intravenous.~Placebo Administered orally three times daily. | 3 | 9 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- 1 year
Source ClinicalTrials.gov
Trial
- Title
- Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases
- NCT number
- NCT00115349
- Phases
- PHASE2
- Conditions
- Cardiovascular Diseases, Heart Diseases, Beta-Thalassemia
- Interventions
- Deferoxamine, Deferiprone (L1)
- Lead sponsor
- Carelon Research
- Results first posted
- 2014-01-14
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00115349?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00115349-sae